MIFH
MBRX icon

Migdal Insurance & Financial Holdings’s Moleculin Biotech MBRX Stock Holding History

Migdal Insurance & Financial Holdings’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-4
Closed -$2K – 656
2021
Q4 		$2K Sell
4
-2
-33% -$1.77K ﹤0.01% 667
2021
Q3 		$7K Buy
+6
New +$7.01K ﹤0.01% 621

Other funds holding MBRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SPC
Sigma Planning Corp Ann Arbor, Michigan $3.6B AUM 24.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Migdal Insurance & Financial Holdings's MBRX Position: Q1 2022 in Review

Migdal Insurance & Financial Holdings sold out of Moleculin Biotech (MBRX) in Q1 2022, closing a stake of 4 shares — an estimated $2K sold.

Migdal Insurance & Financial Holdings first reported a position in MBRX in Q3 2021 and held it in 2 quarters. The position peaked at $7K in Q3 2021. 22 funds tracked by Wall St. Rank hold MBRX as of Q1 2022.

  • Migdal Insurance & Financial Holdings reported no remaining Moleculin Biotech position as of Q1 2022 after selling out during the quarter.
  • Migdal Insurance & Financial Holdings sold 4 Moleculin Biotech shares in Q1 2022, an estimated $2K.
  • Migdal Insurance & Financial Holdings first reported a position in Moleculin Biotech in Q3 2021 and held it in 2 quarters.
  • Migdal Insurance & Financial Holdings's Moleculin Biotech position peaked at $7K in Q3 2021.
  • 22 funds tracked by Wall St. Rank held Moleculin Biotech as of Q1 2022.

Based on Migdal Insurance & Financial Holdings's 13F filing for Q1 2022, filed 2 May 2022.